The New England journal of medicine, 2019-02, Vol.380 (8), p.711-719
- Carrier, Marc
- Abou-Nassar, Karim
- Mallick, Ranjeeta
- Tagalakis, Vicky
- Shivakumar, Sudeep
- Schattner, Ariah
- Kuruvilla, Philip
- Hill, Danny
- Spadafora, Silvana
- Marquis, Katerine
- Trinkaus, Mateya
- Tomiak, Anna
- Lee, Agnes Y.Y
- Gross, Peter L
- Lazo-Langner, Alejandro
- El-Maraghi, Robert
- Goss, Glenwood
- Le Gal, Gregoire
- Stewart, David
- Ramsay, Timothy
- Rodger, Marc
- Witham, Debra
- Wells, Philip S
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Carrier, Marc
- Abou-Nassar, Karim
- Mallick, Ranjeeta
- Tagalakis, Vicky
- Shivakumar, Sudeep
- Schattner, Ariah
- Kuruvilla, Philip
- Hill, Danny
- Spadafora, Silvana
- Marquis, Katerine
- Trinkaus, Mateya
- Tomiak, Anna
- Lee, Agnes Y.Y
- Gross, Peter L
- Lazo-Langner, Alejandro
- El-Maraghi, Robert
- Goss, Glenwood
- Le Gal, Gregoire
- Stewart, David
- Ramsay, Timothy
- Rodger, Marc
- Witham, Debra
- Wells, Philip S
- Titel
- Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
- Ist Teil von
- The New England journal of medicine, 2019-02, Vol.380 (8), p.711-719
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- Elektronische Zeitschriftenbibliothek - Freely accessible e-journals
- Beschreibungen/Notizen
- Patients receiving cancer treatment who had an intermediate-to-high risk of venous thromboembolism were randomly assigned to apixaban or placebo for 6 months. VTE was noted in 4.2% of patients receiving apixaban and 10.2% of those receiving placebo, a significant difference. Major bleeding occurred in 3.5% of patients with apixaban and in 1.8% with placebo.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1814468Titel-ID: cdi_hal_primary_oai_HAL_hal_02052475v1
- Format
- –
- Schlagworte
- Administration, Oral, Aged, Antineoplastic Agents - therapeutic use, Bleeding, Cancer, Cardiology and cardiovascular system, Chemotherapy, Clinical trials, Disease prevention, Double-Blind Method, Drug therapy, Embolisms, Evidence-based medicine, Factor Xa Inhibitors - adverse effects, Factor Xa Inhibitors - therapeutic use, Female, Health risk assessment, Hemorrhage - chemically induced, Human health and pathology, Humans, Incidence, Intention to Treat Analysis, Kaplan-Meier Estimate, Life Sciences, Male, Medical research, Middle Aged, Morbidity, Neoplasms - complications, Neoplasms - drug therapy, Patients, Pyrazoles - adverse effects, Pyrazoles - therapeutic use, Pyridones - adverse effects, Pyridones - therapeutic use, Risk Factors, Thromboembolism, Thrombosis, Venous Thromboembolism - etiology, Venous Thromboembolism - prevention & control